Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Merck & Co., Inc.
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
August 25, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Leslie A. Brun Resigns from Merck Board of Directors
August 20, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
August 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
August 11, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma
August 10, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
August 10, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
August 05, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer
July 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Second-Quarter 2021 Financial Results
July 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Fourth-Quarter 2021 Dividend
July 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
July 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
July 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
July 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
VERQUVO® (vericiguat) Approved in the European Union
July 21, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021
July 20, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
July 16, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC
July 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021
July 12, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
July 06, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the US
July 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29
June 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
June 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Appoints Michael Klobuchar Chief Strategy Officer
June 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
June 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
June 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Guggenheim Biopharma Strategy Series
June 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All
June 16, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
June 09, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
June 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial
June 03, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.